Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine’s Next Frontier
- Celyad is a small European company working to develop CAR-T immunotherapy in solid tumors.
- The first couple companies to get approvals for CAR-T in solid tumors will become blockbusters.
- Celyad’s profile, as I have discussed below, looks promising, speculative, and interesting.
By Dr. Udaya Kumar Maiya, MBBS, MD, DNB, DCCF-Paris
In the entire field of oncology, perhaps the most disruptive ongoing revolution is the application of Chimeric Antigen Receptor - T Cells or (CAR-T) to cancer immunotherapy. In this therapy, engineered T-cells that express a specific tumor antigen binding domain called Chimeric Antigen Receptor is infused into the patient. As the construct binds to its target domain, the T-cell is activated and attacks the cancer cell with great specificity. Remission rates as high as 94% in late-stage acute lymphoblastic leukemia (ALL) have been observed. While ALL itself is a very curable cancer with high CRs (Complete Remission) seen with HSCT therapy (hematopoietic stem cell transplant), subdued whispers are being heard in laboratory corridors and newsrooms whether cancer has finally found its nemesis.
The full post is available to investor members only. Subscribe here.